CoChat

Metformin is the key factor in elevated plasma growth differentiation factor‐15 levels in type 2 diabetes: A nested, case–control study

Open access
Natali, Andrea, Nesti, Lorenzo, Venturi, Elena, Shore, Angela C., Khan, Faisel, Gooding, Kim, Gates, Phillip E., Looker, Helen C., Dove, Fiona, Goncalves, Isabel, Persson, Margaretha, Nilsson, Jan, on behalf of the SUMMIT consortium · 2019 · Diabetes, Obesity and Metabolism
Cited by 44

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Produced as a tissue defence response to hypoxia and inflammation, growth differentiation factor‐15 (GDF‐15) is elevated in people receiving metformin treatment. To gain insight into the relationship of GDF‐15 with metformin and major cardiovascular risk factors, we analysed the data from the SUMMIT cohort (n = 1438), a four‐centre, nested, case–control study aimed at verifying whether biomarkers of atherosclerosis differ according to the presence of type 2 diabetes and cardiovascular disease. While in univariate analysis, major cardiovascular risk factors, with the exception of gender and cholesterol, increased similarly and linearly across GDF‐15 quartiles, the independent variables associated with GDF‐15, both in participants with and without diabetes, were age, plasma creatinine, N‐terminal pro‐brain natriuretic peptide, diuretic use, smoking exposure and glycated haemoglobin. In participants with diabetes, metformin treatment was associated with a 40% rise in GDF‐15 level, which was independent of the other major factors, and largely explained their elevated GDF‐15 levels. The relatively high GDF‐15 bioavailability might partly explain the protective cardiovascular effects of metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13519

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 44

Metadata

Authors
Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., Gooding, K., Gates, P. E., Looker, H. C., Dove, F., Goncalves, I., Persson, M., Nilsson, J., & on behalf of the SUMMIT consortium
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-10-02
Volume
21
Issue
2
Pages
412-416
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2891296453
Cited by
44
References
5
FWCI
4.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin is the key factor in elevated plasma growth differentiation factor‐15 levels in type 2 diabetes: A nested, case–control study. https://app.cochat.ai/papers/10.1111/dom.13519
The paper
Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., Gooding, K., Gates, P. E., Looker, H. C., Dove, F., Goncalves, I., Persson, M., Nilsson, J., & on behalf of the SUMMIT consortium. (2019). Metformin is the key factor in elevated plasma growth differentiation factor‐15 levels in type 2 diabetes: A nested, case–control study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.